Loading...

Home
ETF
TRDA

TRDA

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

TRDA News

Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference

Dec 17 2025Globenewswire

Entrada Therapeutics CEO Dipal Doshi to Present at 2026 J.P. Morgan Healthcare Conference

Dec 17 2025Newsfilter

Entrada Therapeutics Grants 40,650 RSUs and Options to New Employees

Dec 04 2025Globenewswire

5AM Venture Sells Its Viking Stake—Wise Decision or Lost Chance?

Nov 18 2025NASDAQ.COM

5AM Venture Exits MoonLake Following a Challenging Year: Key Highlights to Note

Nov 18 2025NASDAQ.COM

3 'Strong Buy' Stocks to Consider Now with Potential Upside Exceeding 125%, Analysts Say (10/24/2025)

Oct 24 2025TipRanks

Entrada (TRDA) Q2 Revenue Drops 98%

Aug 06 2025NASDAQ.COM

Validea Kenneth Fisher Strategy Daily Upgrade Report - 7/1/2025

Jul 01 2025NASDAQ.COM

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 03 2025Newsfilter

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 02 2025Newsfilter

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28 2025Newsfilter

Validea Kenneth Fisher Strategy Daily Upgrade Report - 5/7/2025

May 07 2025NASDAQ.COM

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Mar 24 2025Newsfilter

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy

Feb 24 2025Benzinga

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 24 2025Newsfilter

Entrada announces FDA removal of clinical hold on ENTR-601-44

Feb 24 2025Business Insider